Home / Events / Goodbye Humira, Hello Future


Goodbye Humira, Hello Future

Available On Demand

Biosimilar versions of adalimumab have launched in the U.S., ending blockbuster therapy Humira’s lengthy market exclusivity and long-running commercial dominance. In parallel, in the creation of the Inflation Reduction Act (IRA), the U.S. joins Europe and other major markets in constraining the opportunity for medicines during their market exclusivity window. The life sciences industry now seeks to understand how the vision for commercial success will evolve into the future, while in parallel navigating the emergence of artificial intelligence (AI) and other general-purpose technologies (GPTs) that present both massive opportunities and further uncertainties.

Join Maximilian Hunt, a Partner in Trinity Life Sciences’ Evidence, Value, Access and Pricing (EVAP) practice, as he moderates a lively panel discussion around a series of provocative topics from our latest blog post “The Last Mega Blockbuster Drug: Goodbye Humira, Hello Future” to help you evolve your thinking around the future of the life sciences industry.

Key Webinar Topics

  • How does the lifecycle of Humira compare with blockbusters past and future?
  • How is the landscape evolving after the introduction of the Inflation Reduction Act in 2022?
  • How can pharma leverage emerging technologies such as AI and other GPTs?


Sign up for the latest intelligence

By signing up, you are agreeing to our Privacy Policy.

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.